Search company, investor...

Compare Philogen vs Sanomune

Customers evaluate the quality of Philogen's products using the following success metrics.

Overview

Philogen is 28 yrs old and is based in Italy.

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications.

Sanomune

Sanomune is 25 yrs old and is based in Canada.

Sanomune is a private biotech start-up focused on neurological and autoimmune diseases. The company's technology is based on the repurposing of a safe, oral biological to treat large market indications. Sanomune's lead product, SAN-61, is a potential first-in-class treatment targeting the dual hallmark pathologies of Alzheimer's (AD): amyloid beta plaque deposition and the formation of neurofibrillary tangles. No other known therapy can effectively target both aspects of the disease. Sanomune's pipeline also includes products for rheumatoid arthritis (RA) multiple sclerosis (MS), stroke and diabetes. One patent has issued and six others have been filed. Sanomune is developing a recombinant form of its core biological as well as a nasal delivery device. With a $1.1 million Series A financing, Sanomune has secured compelling efficacy data, a strong IP position and has submitted, just recently, for regulatory approval to begin Phase II trials for AD and RA.

Founded Year